Last reviewed · How we verify
Beta-lactam oral challenge
At a glance
| Generic name | Beta-lactam oral challenge |
|---|---|
| Sponsor | Meir Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department (PHASE1)
- Geisinger Antibiotic Allergy Pilot Program: Assess and Address (EARLY_PHASE1)
- Direct Oral Challenges in Private Practice Setting to Delabeling Children With Beta-lactam Allergy
- Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge (PHASE3)
- Oral Penicillin Challenge and Allergy De-labeling in Children (PHASE4)
- Oral Challenge in the Pediatric ED (PHASE4)
- Evaluation of a Direct Oral Penicillin Challenge in a Rural Community (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-lactam oral challenge CI brief — competitive landscape report
- Beta-lactam oral challenge updates RSS · CI watch RSS
- Meir Medical Center portfolio CI